pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Journavx · news · pharmadog
← back to Journavx
News mentioning Journavx
20
stories
14d
How J&J paved the way for Compass’ coming psychedelic drug launch
biopharma dive
Aug 21, 26
Werewolf and Ambros to tie the knot in $150M rare disease deal
biospace
Aug 19, 26
Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
biospace
Aug 17, 26
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
Aug 10, 26
BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
biospace
Aug 7, 26
Latigo IPO raises nearly $350M for pain drug development
biopharma dive
Aug 7, 26
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
Aug 4, 26
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
Aug 3, 26
STAT+: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
stat
Aug 3, 26
STAT+: Is there a pharma mega-merger in the making?
stat
Aug 3, 26
STAT+: BioNTech names Guido Oelkers its new CEO
stat
Jul 31, 26
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
stat
Jul 31, 26
Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial
endpoints
Jul 30, 26
STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment
stat
Jul 29, 26
NSF testing new Ph.D. model giving trainees academic and industry experience
stat
Jul 29, 26
STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
stat
Jul 20, 26
Pain drugmaker Latigo outlines plans to go public
biopharma dive
Jul 19, 26
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
fiercebiotech
May 12, 26
A year after Vertex’s big launch, pain drug research faces a pivotal moment
biopharma dive
May 5, 26
Vertex earnings get muted investor response
biopharma dive
